Identification of tumour necrosis factor apoptosis inducing ligand (TRAIL), a TNF family ligand, sparked a torrent of research, following an initial observation that it could kill tumour cells, but spare normal cells. Almost a decade after its discovery, and with five known receptors, the true physiological role of TRAIL is still debated and its anti-tumorigenic properties limited by potential toxicity. This review takes a comprehensive look at the story of this enigmatic ligand, addressing its remaining potential as a therapeutic and providing an overview of the TRAIL receptors themselves.
TRAIL
Tumour necrosis factor apoptosis inducing ligand (TRAIL, Apo2L) is a type II membrane bound TNF family ligand that is highly homologous to cytotoxic FasL, displays widespread expression and is up-regulated on lymphocyte activation [1, 2] . Crystal structures have shown that, like other TNF ligands, it occurs as a trimer (Fig. 1 ). It can be cleaved from the membrane by cysteine proteases to generate a soluble form of the ligand [3] , and specifically from activated monocytes and neutrophils [4] . Its main function is to induce apoptosis and activate the transcription factor NF-κB.
Interest in TRAIL mounted, following the observation that TRAIL could selectively kill cancer cells but not normal cells, and consequently, several receptors for TRAIL quickly emerged (Fig. 2) . Initially, death receptor 4 (DR4/TRAILR-1) was the only known TRAIL receptor, but its widespread expression on both malignant and normal cells, at similar levels, did not explain the observed TRAIL selectivity [5] . A second receptor, death receptor 5 (DR5/TRICK-2/KILLER/TRAILR-2), was then identified using the sequence of the intracellular death domain of DR4 in an expressed sequence tag (EST) database search [6] [7] [8] . However, DR5 was also widely expressed on both normal and malignant cells. Another EST database search was carried out, this time using the extracellular sequence of the death receptors, the putative TRAIL binding region, and two new receptors were identified: decoy receptor 1 (DcR1/LIT/ TRID/ TRAILR-3) and decoy receptor 2 (DcR2/TRUNDD/ TRAILR-4) [7, [9] [10] [11] [12] [13] . DcR1 had no death domain and was anchored to the membrane via a glycophosphatidyl inositol (GPI) tail, whereas DcR2 was found to have a truncated and non-functional death domain. Finally, a fifth receptor for TRAIL, osteoprotegerin (OPG), exists in a dimeric, soluble, secreted form [14] . Expression of the so-called decoys (DcR1 and DcR2) was initially found to be restricted to normal cells, and researchers thought they had found the answer for TRAIL's selectivity [11, 15] . Thus, it was proposed that the decoys on normal cells could sequester TRAIL and divert it away from the death receptors, whereas absence of the decoys on cancerous cells left them susceptible to TRAIL-induced death.
A role for TRAIL in cancer therapy
Simple transfection experiments showed that addition of the decoys conferred protection from TRAIL-mediated killing [9, 10, 16] . It appeared that cancer cells had left themselves 'unguarded' through the loss of decoy expression. Hopes for TRAIL as the new 'golden bullet' for cancer cells grew, and several in vivo studies have shown promising use of recombinant TRAIL with marked tumour regression [17, 18] . In multiple myelomas it overcomes the drug resistance that so far has prevented an effective cure for this cancer [19] . Studies also suggest that an increased potency against tumours is achieved when TRAIL is administered as a combination therapy with preexisting anti-cancer drugs. An increase in TRAIL-induced apoptosis was seen with etoposide, AraC and doxorubicin; the phenomenon attributed to an increase in DR5 levels, which can be up-regulated in response to DNA damage [20, 21] ; the same effect was observed in glioma cells [22] . Similarly, chemotherapy augments TRAIL-induced apoptosis in breast cancer and allowed TRAIL-sensitisation of the AIDS sarcoma [23, 24] , and human hepatocellular carcinoma cells were markedly sensitized to TRAIL with 5'Fluorouracil (5'FU) [25] . In addition, enhancement of TRAIL sensitivity has been reported when used with irradiation [26] .
However, the true potential for TRAIL as a therapeutic is marred by a controversial and as yet unresolved debate over its potential toxicity to human hepatocytes. In vitro studies showed that normal human hepatocytes were sensitive to TRAIL [27] . Another study proposes a critical role for TRAIL in hepatic cell death and inflammation [28] . In a mouse disease model of hepatitis, a marked increase in TRAIL expression, though not the receptors, was observed, and injection of soluble DR5 provided some relief. It has been argued that the soluble and membranebound forms of TRAIL may have differing activities, as well as different functions across species, but liver damage in mice also arose in response to membrane-bound TRAIL [3, 29] . TRAIL apoptosis of human stellate cells, thymocytes, prostate epithelial cells and neural cells has also been observed under certain conditions, raising the concern that these too may be damaged by a TRAIL therapeutic [30] [31] [32] [33] [34] . Whilst experiments had shown effective killing of transformed cells with FasL, the massive systemic toxicity and the lethal effect of FasL and anti-Fas antibody, called an early halt to any therapeutic advances [35] . Likewise, despite the observed anti-cancer properties of TNFα, problems with TNF-toxicity at high doses and even pro-angiogenic properties have also limited its use in cancer treatment 5 (reviewed in [36] ). So, the possible toxicity of TRAIL is an added disappointment. Hopes were raised with a simple human DR5 monoclonal antibody, that can mimic TRAIL by causing receptor clustering, and was shown to lack toxicity against human hepatocytes in vitro, while TRAIL itself remained toxic [29] . The antibody remained effective at killing tumour cells in vivo, but such antibody killing requires crosslinking with dynabeads to be effective, which can happen through Fc receptors in vivo. Thus, a human antibody against the death receptors that can induce apoptosis in tumours but not the liver, has yet to be found.
Among the drive for therapeutics, studies of numerous normal and tumour cell lines have failed to show a definite correlation between expression of the TRAIL receptors, at both the mRNA and protein level, and protection from, or susceptibility to, apoptosis [37] [38] [39] . Current literature describes a myriad of ways in which sensitivity to TRAIL may be controlled which is often cell-type dependent. In one case the high levels of death receptors on the surface but a lack of sensitivity were explained by the presence of a polymorphism in the death domain of DR4, leading to dominant negative inhibition of signalling [21] . However, the presence of internal regulators of apoptotic machinery such as cellular FLICE like inhibitory protein, cFLIP (FLAME, CASH, CLARP and MIT-1), an inhibitor of caspase activation, was another important determinant [21, 40] . More recently, the synergistic effect of 5'FU along with TRAIL in killing cancer cells was attributed to the down-regulation of cFLIP [25] . Loss of cFLIP using RNA interference demonstrated a crucial role for this internal regulator. The status of p53, a tumour suppressor gene that responds to DNA-damage and can up-regulate DR5, was also influential in some cell lines [41, 42] . The presence or absence of the decoys was soon found to be an unreliable indicator of sensitivity, and the original hypothesis assuming a simple difference between the expression of the death receptors and the decoys, was in doubt. Indeed, in some tumours, up-regulation of the decoys and TRAIL expression has been implicated as an immune evasion mechanism [43] . It is now apparent that different tumour cell lines respond to TRAIL in different ways, and highlights the importance of treating each type of cancer individually. The future of TRAIL as a cancer therapy, for the time being, may be limited to a role in local treatment of tumours in conjunction with current DNA-damaging therapies, although effective targeting of internal regulators in conjunction with TRAIL might also be hopeful.
Functions of TRAIL
While the activity of TRAIL as an anti-tumour agent has been heavily pursued, the true function of TRAIL under normal physiological conditions remains unanswered. TRAIL became a prime candidate for the negative selection of immature thymocytes, following lack of evidence for the involvement of Fas/FasL, this too an area of much controversy. Studies using lpr mice (with Fas mutations) have suggested that Fas may modulate negative selection, and they also show a crucial role for Fas in T-cell development [44] . However, other studies have shown that Fas deficient mice develop a normal T-cell repertoire [45] . It is now accepted that the major role of Fas is in the deletion of peripheral T-cells and in activation induced cell death (AICD) (reviewed in [46] ).
In our laboratory, a study using cultured thymocytes and anti-CD3 treatment as a model for negative selection, showed an activation-induced increase in TRAIL sensitivity of thymocytes, but not peripheral T-cells [32] . However, death of activated thymocytes was found to be TRAIL-independent since it could not be blocked using soluble DR5-Fc. Thus, TRAIL did not appear to be a major mediator of negative selection. This result was confirmed in TRAIL-deficient mice, which showed no abnormalities in lymphoid or myeloid homeostasis or function [47] . Interestingly, a second study of TRAIL knockout mice presents a more crucial role for TRAIL [31] . They describe an enlarged thymus and attribute this to a defect in thymocyte apoptosis, claiming an essential role for TRAIL in thymic deletion. The TRAIL -/-mice showed increased numbers of immature thymocytes and a failure to induce apoptosis of activated T-cells both in vitro and in vivo. They also proposed an important role for TRAIL in mediating auto-immunity, showing that the TRAIL deficient mice have an increased susceptibility to collagen-induced arthritis and streptozotocin-induced diabetes. The TRAIL -/-mice were more prone to disease development and showed accelerated disease progression. However, the mice do not develop spontaneous autoimmune disease in the first few months.
If TRAIL is a key player in negative selection, it is clear that it cannot work alone or through its conventional route. Mice lacking FADD or with caspase-8 blocked via transgenic CrmA (a viral inhibitor of caspase-8), two key components in the TRAIL signalling pathway, showed no thymic abnormalities [48, 49] . Rather, mice deficient for FADD showed proliferative defects in their T-cell populations that were independent of caspase-8. Interestingly, mice deficient for Bim, a Bcl-2 family pro-apoptotic component, have severe defects in thymic deletion [50] . An elegant hypothesis was proposed to account for much of the evidence so far [51] : following TCR-stimulation, TRAIL receptors are up-regulated; their subsequent engagement induces activation of JNK which in turn inactivates Bcl-2. The now inactive Bcl-2 then releases Bim, which can trigger death via the mitochondrial pathway. Finally, a third study of TRAIL -/-mice refute the findings by Lamhamedi-Cherradi et al [52] . Using four different models for negative selection they argue that TRAIL has no role in early thymic deletion.
With a failure to identify a true role for TRAIL, many now believe that the initial observation of anti-tumourigenicity is in fact its true function, and that TRAIL fulfils an immune surveillance mechanism within the body in the innate immune response, against both tumours and virusinfected cells. It has been shown to be up-regulated on NK-cells in response to IFNγ, particularly liver NK cells, and serves an anti-metastatic function [53, 54] . Similarly, IFNγ-stimulated monocytes, peripheral blood T-cells, dendritic cells and CD4
+ T-cells demonstrate TRAILdependent anti-tumourigenicity [55] [56] [57] . IFNγ-dependent events also govern cytomegalovirus (CMV) up-regulation of TRAIL and its activity against virus-infected cells [58] . HIV-infection reportedly sensitises previously resistant Tcells to TRAIL-mediated death [59] , an observation supported by other work [60, 61] . Similarly, TRAIL resistant colonic epithelial cells are rendered sensitive upon infection with human CMV [62] . This immune surveillance role for TRAIL is also supported by observations in TRAIL -/-mice [47] . While the mice show no spontaneous tumour development, upon challenge with a TRAIL sensitive cancer cell line they develop tumours more rapidly than the wild type mice, and these tumours occur almost exclusively in the liver.
The many cancer studies have revealed a definite role for TRAIL in the liver, and it has been postulated that this waste ground for dying lymphocytes is cleared through the actions of TRAIL [53] . This surveillance role is also thought to mediate protection of cells at sites of immune privilege, such as along the syncitiotrophoblast of the placenta [63] and in the eye [64] . Some research suggests a role in the deletion of B-cells [65] , and another study describes TRAIL as a negative regulator of erythropoesis [66] , although no anaemia was observed in TRAIL -/-mice [47] . New evidence that TRAIL can exhibit potent proangiogenic properties, along with the anti-tumourigenicity heavily discussed, suggests a Jekyll and Hyde persona for TRAIL [67] .
Adverse affects of TRAIL include the discussed role in hepatic disease [27] , induction of apoptosis and inflammatory gene expression in endothelial cells [68] , and its role in reovirus-induced apoptosis, which is IFNγ-mediated and a major contributor to the viral pathology [69] . While all these data are important in discerning the true role of TRAIL, mouse models are somewhat limited since mice only express one death receptor, most closely related to human DR5 [70] . Two mouse homologues of human DcR1 and 2 also exist, termed mDcTrailr1, and msDcTrailr2. MsDcTrailr1 has a GPI-anchor, whereas msDcTrailr2 has two splice variants, the longer form with a transmembrane domain and a short cytoplasmic region and a short soluble secreted form expressing only the ECD [71] . These have the highest degree of homology to their human counterparts in the ligand binding region, but have three disulphide bonds in the first CRD, compared with only one in DcR1 and 2. These distinct differences in structure suggest independent evolutionary origins from the human receptors, further limiting the mouse model in studies of the TRAIL/TRAIL receptor axis. In addition, these murine models do not address long-term effects such as ageing, and true disease challenge.
TRAIL receptor triggering
The crystal structure of a complex between TRAIL and DR5, solved in our laboratory and others, revealed the trimeric ligand interdigitated with three monomeric receptors [72] [73] [74] . The receptors are positioned neatly at the interfaces between the ligand monomers with the contact surface in the second and third CRD (Fig. 3) . Such crystal complexes of other members of this family led to the 'ligand induced trimerisation model', in which the incoming trimeric ligand recruits three receptor molecules (Fig. 4) . This induced juxtaposition of the intracellular receptor domains is then sensed inside the cell and facilitates the recruitment of downstream signalling components, triggering the internal signalling cascade. The ligand-induced trimerisation model was consequently widely accepted and became the paradigm for receptor triggering in the TNFR superfamily. However, studies of both Fas and TNFR1 defined a ligand-independent oligomerisation domain in the extracellular region, termed the pre-ligand assembly domain (PLAD) [75, 76] .
These observations invoked consideration of an alternative model for receptor triggering, in which the receptors could pre-associate prior to ligand binding. The PLAD was shown to be necessary for subsequent ligand binding, and was proposed as the mechanism by which the sometimes promiscuous TNF family ligands are as- sured a homotypic trio of receptor molecules in any given complex (Fig. 5 ). If such multimeric assemblies do exist, it would suggest that signalling involves a large scale recruitment of receptor at the cell surface leading to a mosaic model of multi-clustering (Fig. 6) . Whether a distinct PLAD exists for the TRAIL receptors has not been shown. However, unlike Fas and TNFR1, they have only a partial CRD1 (putative PLAD) with one cysteine bond compared to the usual complement of three.
On the receiving end
Disappointments with TRAIL as a therapeutic have led researchers back to targeting death via the TRAIL receptors themselves. The TRAIL receptors belong to the tumour necrosis factor receptor (TNFR) superfamily, also known as the nerve growth factor receptor superfamily (NGFR), and are related by virtue of their structure. They are type I transmembrane proteins with a common structural framework defined by the presence of cysteine residues in highly conserved locations within the extra-cellular domains, termed cysteine-rich domains (CRD) (reviewed in [77] ).
Death receptor 5
Death receptor 5 is a non-glycosylated protein with 58% overall homology to DR4, the greatest homology in the intracellular death domain. It has one partial CRD (with only one cysteine bond, compared to the full complement of three) and two full CRDs in the extracel- lular domain. It is expressed in a wide range of tissues but is strongly up-regulated on activated lymphocytes. Interestingly, there are two forms of DR5 which result from alternative splicing: DR5A/TRICK2A (short) and DR5B/TRICK2B (long). They differ in the presence of a 23 amino acid extension between the transmembrane domain and the start of the CRDs [8] . These two isoforms do not appear to have distinct functions and it has been suggested that the longer form may have arisen due to retention of an intron, since the sequence at either end matches that of a consensus splice site. DR4 does not contain this additional sequence and is therefore more closely related to DR5A. Over-expression of DR5 through transient transfection causes spontaneous cell death, due to clustering of the death domains [8] .
The main function of DR5 is in its role as a death receptor on many different cell-types. A specific physiological role for either DR4 or DR5 has yet to be defined, although the existence of two death receptors for the same ligand might suggest an essential role in tissue homeostasis. Reports in the literature have been driven by the TRAIL sensitivity of cancer cell lines. Specifically, up-regulation of DR5 has been reported in response to treatment with DNA-damaging cancer therapeutics [20] . In addition, loss of function of DR5 in head, neck and gastric carcinomas may demonstrate a role for the apoptotic activity of DR5 in mediating uncontrolled proliferation [78, 79] . Hence, DR5 is gaining a reputation in the role of a tumour regulator.
A link between DR5 and the status of the p53 tumour suppressor gene has also been extensively studied. Mutations in the p53 gene are some of the most predominant occurring in over 50% of cancers. This transcription factor controls a crucial checkpoint in the cell cycle and can mediate apoptosis of damaged cells by two mechanisms: via the mitochondrial pathway through generation of reactive oxygen species (ROS), and via a receptor-mediated pathway involving DR5 (reviewed in [41, 80] ). Studies have shown that DR5 is up-regulated in response to γ-irradiation, in particular in the spleen and small intestine, and that this is a p53-mediated event [81] . The presence of p53-response elements within the DR5 promoter has also been shown [82] .
Specifically, a role for DR5 in mediating apoptosis of synovial fibroblasts has been described [83] . In rheumatoid arthritis pathology is driven by proliferating synovial fibroblasts that exhibit properties similar to transformed cells, and secrete metalloproteinases (MMPs) that exacerbate inflammation within the joint. These cells up-regulate DR5 expression and seemingly escape TRAIL-mediated apoptosis. Whether this is the cell's own attempt to stunt proliferation is unknown. However, they were effectively targeted and killed with a monoclonal antibody against DR5. This same monoclonal antibody (TRA-8) has been shown to kill cancer cells effectively without hepatic toxicity, showing diverse potential as a future therapeutic [29, 84] .
Death receptor 4
Death receptor 4 was the first of the TRAIL receptors to be identified [5] . Functionally, its story is similar to that of DR5, and may play an identical immune surveillance role, since its major function is the induction of apoptosis. A clear distinction between the roles of DR4 and 5 has yet to be defined, but it is likely that there is some functional redundancy between the two. Several mutations within DR4 have been reported in cancer cells [85] [86] [87] . Specifically, a polymorphism in the ligand binding domain of DR4 has been linked to a higher incidence of bladder cancer [88] , and the expression of DR4 in colon cancers was linked to a favourable prognosis [89] . Like other cancers, the presence of DR4 renders them susceptible to killing via TRAIL [90] . DR4, like DR5, is also p53-inducibe, and treatment of tumours has been shown to be more effective in the presence of DNA-damaging therapeutics [91, 92] . It can be down-regulated by adenovirus proteins [93] , but conversely, up-regulated by hepatitis B [94] .
The decoy receptors
Cloning of the decoy receptors rapidly followed that of the death receptors. DcR1 is GPI-tethered to the membrane, and is much less widely expressed than the other TRAIL receptors; transcripts were found predominantly on peripheral blood lymphocytes (PBLs) [10, 13] . It appears to have minimal signalling capacity, and unlike the death receptors, over-expression does not cause apoptosis, but instead blocks it. Its ability to inhibit apoptosis has been shown through transient transfection and through inhibition of TRAIL-induced apoptosis by DcR1-Fc [10] . The possibility that it can elicit direct signalling via its GPI 
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anchor has not been studied, but with increasing research describing the potency of GPI signalling, this certainly invites investigation [95] . DcR1 has five glycosylation sites, and research from our laboratory suggests that deglycosylation can increase its affinity for TRAIL, providing a possible regulatory mechanism (unpublished data). The existence of soluble DcR1 has also been shown, although experiments with PI-PLC, an enzyme that cleaves many GPI-linked proteins, showed minimal cleavage of 30%, compared to 80% with a control protein [10] . DcR2 has a high degree of homology to the other TRAIL receptors, approximately 58-70%, and is widely expressed [9] . It has three potential N-glycosylation sites and a truncated intracellular domain, lacking 52 of the 76 amino acids that encode the predicted death domain, but overexpression does not induce death [6] . A physiological role for either of the decoy receptors has not been shown; instead reports have been concerned with their presence or absence on tumours, and their ability to inhibit cell death. There is evidence to suggest that the decoy receptors are also up-regulated in response to p53-sensed DNA damage [16] . This does not fit well with an immune surveillance role for the death receptors in the elimination of DNAdamaged cells, where up-regulation of the decoys would surely counteract this event. However, the four TRAIL receptors are located in the same chromosomal region (chromosome 8p21-22), so it is possible that in this system of p53 over-expression, otherwise weak signals for the decoys were amplified through the DR4 and 5 promoters.
The real decoy?
Discovery of the truncated TRAIL receptors posed several questions. What was their true physiologic role? Were they really present as dummy receptors to evade death receptor killing and if so, how was their expression regulated with respect to the functional death receptors? There are currently four major hypotheses regarding their action (Fig. 7) . The first is the classic decoy hypothesis, whereby they are concomitantly expressed with the death receptors and compete for binding to TRAIL (Fig. 7A) . If this competition theory is to hold, then one might expect the decoys to have a higher affinity for TRAIL in order to efficiently sequester TRAIL from the death receptors. Several studies have measured ligand binding of the TRAIL receptors [9, 10, 14, 96] . The meaning of these numbers is complicated by the use of Fc-fusions (bivalent) binding a trimeric TRAIL, so provide only a measure of avidity rather than true affinity. One study concluded that TRAIL binds equally well to DR4, DR5 and DcR1 [10] , yet a second describes a temperature-dependent rank order of 'affinities' (at 37 o C), with DR5 the greatest (Kd < 2 nm), followed by DR4, DcR1 and OPG, respectively; at 4 o C and 25 o C the binding measurements were comparable [96] .
So, these studies provide little clues towards the true mechanism, but this hypothesis remains the most favoured, since transfection experiments show that the decoys can afford protection from TRAIL-mediated killing [9, 10] . The specific up-regulation of DcR1 was found in tumours of the gastrointestinal tract, possibly as a means of immune evasion [97] . However, such decoy activity within a physiological setting has yet to be proven, and many studies have found conflict between the sensitivity of a particular cell line and the expression pattern of the TRAIL receptors, suggesting an increased complexity to this mechanism [39] . Up-regulation of DcR1 in response to TNFα-stimulated NF-κB has been shown [98] . DcR1 was then able to confer protection from TRAIL-mediated killing, even though the levels of the other receptors were unaffected.
The second hypothesis is that the decoys are able to form mixed receptor complexes with the two death receptors, leading to an ineffective death inducing signalling complex, DISC (Fig. 7B) . There is no current explanation for the mechanism by which TRAIL affords a homotypic trio of receptors in any given complex, and co-immunoprecipitation experiments show some evidence for heteromeric clusters of DR4 and 5, although these were less abundant [99] . In the case of DcR1, the presence of a GPI tail is likely to locate it in a distinct membrane domain to the death receptors, rendering such interactions unlikely, though this hypothesis cannot be eliminated for DcR2. Thirdly, there is some evidence to suggest that whilst DcR2 cannot activate death, it can activate NF-κB [9, 100] , although others have been unable to show this [16] . It is proposed that the subsequent up-regulation of anti-apoptotic genes by DcR2 might antagonise the death signal (Fig. 7C) . Alternatively, even if DcR2 does not signal for either death or NF-κB, its intracellular domain may be able to deplete supplies of intracellular adaptors to prevent them binding to either DR4 or 5. However, this seems unlikely as this would mean the inhibition of other death receptors such as Fas and TNFR1. However, deletion studies of DcR2 demonstrated that the first 43 amino acids of the intracellular domain (ICD) were required for inhibition of TRAIL, and that DcR2 lacking its entire ICD does not protect from TRAIL-mediated death [16] . This therefore suggests that some intracellular mechanism plays an important role in any potential 'decoy' function.
Finally, the existence of a pre-ligand assembly domain (PLAD) in both Fas and TNFR1 raises the question as to whether such a domain exists in the TRAIL receptors [75, 76] . The four membrane-bound TRAIL receptors have comparable CRD architecture, and with such a high degree of homology in the extracellular domains, could cross-PLAD interactions be the answer to decoy activity?
If a pre-assembled trio of death receptors were to include one of the decoys, signalling upon ligand binding would be stunted (Fig. 7D) . Might lateral receptor interactions define a novel flow of information between these molecules? This mechanism for inhibition presents a situation in which competition for the ligand plays no direct role, and could explain decoy activity despite differing affinities for TRAIL. Again, the location of DcR1 within lipid rafts would make this hypothesis less likely for DcR1, but it must be considered that DcR1 and 2 might employ different means of decoy activity. Interestingly, one report showed that transient co-transfection of DcR2 with DR5 can protect the cell from the apoptosis that can occur as a result of the death domain clustering of DR5 [16] .
Osteoprotegerin
Osteoprotegerin (OPG) is the only soluble TRAIL ligand, it is heavily glycosylated and occurs primarily as a disulphide linked dimer, although a small proportion can be found in a monomeric form [14, 101] . Unlike the other TRAIL receptors, it has four CRDs, each with only two disulphide bonds, except CRD2 which has three. It acts as a regulator of the development and activation of osteoclasts in bone remodelling. Normally, OPG ligand (also called TRANCE or RANKL) binds to RANK (receptor activator of NF-κB), and stimulates osteoclastogenesis. OPG plays an important role as a decoy competing with RANK for OPGL binding, and the balance of these two receptors forms a regulatory mechanism [101] . OPG also has a role in the regulation of the immune response (reviewed in [102] ). Studies with OPG deficient mice revealed B-cell defects, indicating an important role in B-cell development and maturation [103] . The role of OPG as a receptor for TRAIL is less clear. It has been proposed to serve as a survival factor, forming a second decoy activity by binding to TRAIL, and thus blocking apoptosis [14, 104] . Additionally, recent work demonstrates a potent blocking of RANKL plus macrophage colony stimulating factor (M-CSF) bone resorption, by TRAIL, indicating yet another potential complication for its therapeutic use [105] . This effect was attributed to specific inhibition of the RANKL-induced p38/MAPK pathway. However, TRAIL -/-mice showed no alteration in gross bone density or differentiation of osteoclasts, shed- ding doubt on a prominent physiological role for TRAIL as an OPG regulator, and vice-versa [47] .
TRAIL receptor signalling
The TRAIL receptors DR4 and 5 have two overlapping modes of signalling: the cell death pathway, and a cell survival pathway involving activation of transcription factors. These pathways are distinguished by the formation of distinct complexes involving different internal adaptors (Fig. 8) . The conventional apoptosis pathway is triggered through formation of the DISC [106, 107] . This begins with the recruitment of a dual adaptor molecule, Fas associated death domain (FADD or Mort1). FADD contains its own death domain (at the Cterminus), and since these have a propensity to selfassociate it binds to the trimerised DDs of the Fas receptor complex [108, 109] . At the N-terminus is the death effector domain (DED) which recruits procaspase-8, via its own DED. This oligomerisation drives self-cleavage to generate its active form which then activates other downstream effector caspases, notably caspase-3. The recruitment of FADD in the Fas pathway is well characterised, but the involvement of this adaptor in DR4 and 5 mediated apoptosis has been one of intense debate and conflicting results.
Early work did not find a role for FADD in DR4 and DR5 signalling [5, 7, 11, 110 ], yet others were convinced of FADD involvement [111] [112] [113] . Finally, FADD-deficient cells displayed resistance to TRAIL-mediated death, indicating that FADD played an essential role. Moreover, immunoprecipitation of the endogenous components of the DISC, in several different cell lines, have shown that FADD/caspase-8 are indeed recruited by DR4 and 5 and that cells lacking these are resistant to TRAIL-mediated apoptosis [99, 114, 115] . To conclude this debate, a direct interaction between the death domain (DD) of DR5 and the DED of FADD has now been shown [116] . A similar discrepancy occurred regarding the proposed role of a GTP-dependent adaptor molecule called DAP3. It was reported to link DR4 and 5 to FADD via a high affinity interaction [117] . However, later studies disputed this, claiming it was an artefact of cellular disruption, and showed location of DAP-3 to be exclusively in the mitochondrial matrix, acting as a pro-apoptotic protein through a different mechanism [118] [119] [120] .
Following initial adaptor recruitment, caspases are recruited and then the proteolytic caspase cascade, terminating in cleavage of crucial cellular proteins, begins. Caspase-8 was originally shown to be the initiator caspase in TRAIL signalling, although caspase-10 was also found to be recruited to, and activated, at the DISC [121] . It appeared they were functionally redundant, but it has since been shown that caspase-10 cannot functionally substitute for caspase -8 [122] .
While apoptosis is the major signalling outcome for the TRAIL death receptors, they can also activate survival signals via the transcription factor NF-κB, which can up-regulate anti-apoptotic genes. The induction of NF-κB is thought to be secondary to their ability to signal apoptosis, primarily occurring in a self-regulatory capacity [100, 111], and this is supported by data showing that NF-κB production emanating from the TRAIL receptors is much weaker than that from TNFR1. In addition, whilst activation of NF-κB leads to a marked decrease in TRAIL apoptosis, activation of NF-κB can only occur in TRAIL sensitive cells in the presence of the caspase inhibitor z-VAD-fmk [123] . Other experiments have shown that activation of NF-κB alone is not sufficient for inhibition of apoptosis via DR4 and 5 [100] .
The activation of a second transcription factor, c-Jun, can also occur, but whether this then mediates mainly pro-or anti-apoptotic signals is not clear. There are two distinct signaling pathways for transcription factor activation, which begin with the recruitment of common adaptors [100] . The first step is the recruitment of TRADD, the TNF receptor associated death domain which, like FADD, binds to the death domain through its homologous region [111] . This then recruits another adaptor, receptor interacting protein, RIP, which also binds via a death domain. Receptor interacting protein (RIP) is a serinethreonine kinase capable of stimulating auto-phosphorylation. Finally, TRAF-2 is recruited to RIP and this is the pivotal component for the two pathways, resulting in activation of either the c-Jun NH2-terminal kinase (JNK) pathway mediated via MEKK1/MKK4 or NF-κB, mediated via the NIK/IKK complex.
TRAIL has been shown to activate JNK via both caspase-dependent and independent pathways [124] . Induction of the JNK pathway was shown to have an amplifying effect on TRAIL-induced apoptosis through the intrinsic pathway [125] . There is some evidence to suggest that the JNK pathway is initiated by DR5 but not DR4, and that these receptors have distinct cross-linking requirements for activation [126] . This is the only evidence to suggest a difference in the signalling capacities of these two receptors. However, studies, using monoclonal antibodies against both DR4 and 5, and chemotherapeutic agents, show synergistic activation of the p38 and JNK signalling pathways which can be inhibited by blocking caspase-8 [127, 128] . Such activation seems to be celltype dependent, and whether this occurs in response to TRAIL in a normal physiological setting has not been shown. Activation of the extracellular signal regulated kinase (ERK) signalling has also been described for TRAIL but this is much less well-defined [129] .
Since the signalling components of DR4 and DR5 are the same, i.e. recruitment of FADD and activation of caspase-8 or -10, it has been suggested that the formation of heteromeric complexes between DR4 and DR5 are possible, and that the outcome of their ligation would be functionally indistinguishable. However, two separate studies have shown that whilst DR4 is activated in response to both soluble and membrane-bound TRAIL, DR5 will only respond to cross-linked or membrane-bound TRAIL; DR5 became sensitive to a soluble form of TRAIL upon tethering to a membrane [3, 126] . This result was not reflected in the work by Tecchio et al in which soluble TRAIL released from IFNγ-stimulated monocytes was able to kill both DR4 and 5 expressing cells [4] . Perhaps this difference limits the formation of mixed complexes, which have been shown [99] . TRAIL receptor signalling is subject to regulation from c-FLIP, a high ratio of which is thought to explain cellular resistance to TRAIL apoptosis in some instances [25, 123] . Proteins from the IAP family (Inhibitors of apoptosis) which have a common BIRmotif (baculovirus IAP repeat) can also inhibit caspases and modulate apoptosis, and cell death that is amplified via the mitochondrial pathway will also be subject to regulation via the Bcl-2 superfamily (reviewed in [130] ).
Conclusions
Many of the early experiments in apoptosis were conducted with over-expressed, transfected receptors rather than endogenous ones. It is now a well described phenomenon that over-expression of death receptors can induce cell death via non-specific aggregation of the death domains, the subsequent activation of caspases occurring through trans-proteolysis through weak protease activity possessed by the pro-forms in the 'induced-proximity' mechanism (reviewed in [131] ). This is accepted as dis-tinct from ligand-receptor induced signalling and is not a good model for analysis of the necessary molecular components. It is possible that this phenomenon may explain some of the early misconceptions in defining the signaling pathways. Likewise, the use of monoclonal antibody cross-linking of the receptors is informative of a cell's susceptibility to death under potential therapeutic conditions, but one must be cautious in extracting too much with respect to true signalling mechanisms.
The story of the TRAIL and its receptors is one of complexity, conflicting results and apparent parody. In a system where there is undoubtedly interplay between several receptors, possible redundancy and differing expression and sensitivity between different tissues, this can only be expected. Research on the decoys has been slow to emerge, but it will be interesting to see new data regarding the signalling capacities of both DcR1 and 2, and other possible binding partners. The potential of TRAIL as an effective systemic anti-cancer drug will be limited until the deleterious effects can be regulated within the different tissues, and understanding how the TRAIL receptors regulate themselves will prove crucial to this cause.
